

Freedom of Information Request

Reference Number: [EPUT.FOI.22.2452](#)

Date Received: [1 April 2022](#)

Information Requested:

1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
 - Bevacizumab (Avastin)
 - Dacarbazine (DTIC)
 - Trametinib (Mekinist)
 - Dabrafenib (Tafinlar)
 - Ipilimumab (Yervoy)
 - Vemurafenib (Zelboraf)
 - Nivolumab (Opdivo)
 - Nivolumab + Ipilimumab (Opdivo + Yervoy)
 - Pembrolizumab (Keytruda)
 - Vemurafenib + cobimetinib (Zelboraf + Cotellic)
 - Dabrafenib + Trametinib (Tafinlar + Mekinist)
 - Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
 - Other active systemic anti-cancer therapy [please state]
 - Palliative care only
2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
 - Ipilimumab
 - Ipilimumab AND Nivolumab
 - Nivolumab
 - Pembrolizumab

- Dabrafenib AND Trametinib
 - Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
 - Other active systemic anti-cancer therapy
 - Palliative care only
-

Response:

Essex Partnership University NHS Foundation Trust is a Mental Health, Learning Disability and Community Services Trust and does not offer these services.

Publication Scheme:

As part of the Freedom of Information Act all public organisations are required to proactively publish certain classes of information on a Publication Scheme. A publication scheme is a guide to the information that is held by the organisation. EPUT's Publication Scheme is located on its Website at the following link <https://eput.nhs.uk>